19 Kazia Theraputics Limited Annual Report 2023 Chairman and CEO’s Letter Key Milestones Introduction to Kazia’s CEO Pipeline Review Environment, Society and Governance Financial Reports Broad Clinical Program Ongoing Sponsor Phase Indication Registration PAXALISIB Global Coalition for Adaptive Research II/III Glioblastoma NCT03970447 Weill Cornell Medicine II Glioblastoma ( with ketogenesis) NCT05183204 Alliance for Clinical Trials in Oncology II Brain metastases NCT03994796 Dana-Farber Cancer Institute II Breast cancer brain metastases ( with Herceptin) NCT03765983 Dana-Farber Cancer Institute II Primary CNS Iymphoma NCT04906096 University of Sydney I/II Grade 2/3 IDH-mutant adult gliomas TBD Pacific Pediatric Neuro-Oncology Consortium II DIPG (childhood brain cancer) NCT05009992 Aus. & NZ Children’s Oncology Group II Advanced solid tumours in children TBD ST Jude Children’s Research Hospital I DIPG NCT03696355 Memorial Sloan Kettering Cancer Center I Brain metastases ( with radiotherapy) NCT04192981 EVT801 Kazia Therapeutics I Advanced solid tumours NCT05114668 Paxalisib Investigational, small molecule, potent, brain-penetrant inhibitor of PI3K / mTOR licensed from: PRECLINICLE PHASE 1 PHASE 2 PHASE 3 MARKET Anticipated Glioblastoma & IDH-mutant glioma Common primary brain cancer Final Data 2H CY23 DIPG/Advanced Solid Tumors Childhood brain cancer Initial Data 3Q CY23 AT/RT Childhood brain cancer Further Data 1H CY23 Brain Metastases Cancer that spreads to brain from elsewhere Further Data CY23 Primary CNS Lymphoma Form of non-Hodgkin’s lymphoma Initial Data CY23 Cancers outside the CNS Melanoma; TNBC, Ovarian Further Data CY23 EVT801 Investigational, small molecule, highly specific inhibitor of VEGFR3 licensed from: Advanced Solid Tumors Patients w/ highly treatment-resistant cancer Initial Data 2H CY23 3 studies 3 studies 3 studies 3 studies
RkJQdWJsaXNoZXIy MjE2NDg3